These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24692602)

  • 21. CDP-870 (certolizumab) in rheumatoid arthritis.
    Kaushik VV; Moots RJ
    Expert Opin Biol Ther; 2005 Apr; 5(4):601-6. PubMed ID: 15934837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Certolizumab pegol: in rheumatoid arthritis.
    Duggan ST; Keam SJ
    BioDrugs; 2009; 23(6):407-17. PubMed ID: 19894782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.
    Kaine JL; Kivitz AJ; Birbara C; Luo AY
    J Rheumatol; 2007 Feb; 34(2):272-9. PubMed ID: 17304653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).
    Vavricka SR; Bentele N; Scharl M; Rogler G; Zeitz J; Frei P; Straumann A; Binek J; Schoepfer AM; Fried M;
    Inflamm Bowel Dis; 2012 Aug; 18(8):1523-30. PubMed ID: 21987429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis.
    Launois R; Avouac B; Berenbaum F; Blin O; Bru I; Fautrel B; Joubert JM; Sibilia J; Combe B
    J Rheumatol; 2011 May; 38(5):835-45. PubMed ID: 21239748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.
    Alten R; Bingham CO; Cohen SB; Curtis JR; Kelly S; Wong D; Genovese MC
    BMC Musculoskelet Disord; 2016 May; 17():231. PubMed ID: 27229685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
    Pasut G
    BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe interstitial lung disease following treatment with certolizumab pegol: a case report.
    Lager J; Hilberg O; Løkke A; Bendstrup E
    Eur Respir Rev; 2013 Sep; 22(129):414-6. PubMed ID: 23997067
    [No Abstract]   [Full Text] [Related]  

  • 29. Comment on: A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis.
    Savage EM; Millar AM; Taggart AJ
    Rheumatology (Oxford); 2014 Jun; 53(6):1154-5. PubMed ID: 24681838
    [No Abstract]   [Full Text] [Related]  

  • 30. A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis.
    Glaspole IN; Hoy RF; Ryan PF
    Rheumatology (Oxford); 2013 Dec; 52(12):2302-4. PubMed ID: 23661426
    [No Abstract]   [Full Text] [Related]  

  • 31. [Biological treatment in severe Still's disease--a case report].
    Suszek D; Koszarny A; Jeleniewicz R; Majdan M; Bończak A; Czukiewska A; Koszła B; Kurlej S; Markowicz J; Szymczyk A
    Wiad Lek; 2015; 68(1):104-7. PubMed ID: 26094343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New drugs: Ciclesonide, certolizumab pegol, and bendamustine hydrochloride.
    Hussar DA
    J Am Pharm Assoc (2003); 2008; 48(4):557-61. PubMed ID: 18653436
    [No Abstract]   [Full Text] [Related]  

  • 33. Comment on: A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis: reply.
    Glaspole I; Hoy R; Ryan P
    Rheumatology (Oxford); 2014 Jun; 53(6):1155. PubMed ID: 24681841
    [No Abstract]   [Full Text] [Related]  

  • 34. Anti-TNF-α and risk of infections: the experience in one center.
    Maruotti N; D'Onofrio F; Neve A; Santoro N; Corrado A; Cantatore FP
    Panminerva Med; 2014 Mar; 56(1):31-4. PubMed ID: 24637471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Certolizumab pegol--new possibilities in the treatment of Crohn's disease].
    Lazebnik LB; Kniazev OV
    Eksp Klin Gastroenterol; 2012; (3):100-5. PubMed ID: 22830233
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
    Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Iwai K; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Jul; 24(4):552-60. PubMed ID: 24981319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological agents in monotherapy for the treatment of rheumatoid arthritis.
    Gabay C; Hasler P; Kyburz D; So A; Villiger P; von Kempis J; Walker U
    Swiss Med Wkly; 2014; 144():w13950. PubMed ID: 24723273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16.
    Østergaard M; Jacobsson LT; Schaufelberger C; Hansen MS; Bijlsma JW; Dudek A; Rell-Bakalarska M; Staelens F; Haake R; Sundman-Engberg B; Bliddal H
    Ann Rheum Dis; 2015 Jun; 74(6):1156-63. PubMed ID: 25512675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.